The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Manufacturer enVVeno said it received a "not approvable" letter from the FDA for its investigational VenoValve implant to ...

Walgreens Specialty Pharmacy, which earned $25.9 billion last year from U.S. prescription revenue, has expanded its limited distribution drug portfolio to 265 medications, the company said Aug. 19. ...

The company revealed that Walgreens Specialty Pharmacy has broadened its limited distribution drug (LDD) portfolio to cover ...

Advocates for HIV prevention are calling a newly approved injectable medication a major step in eliminating the spread of the ...

Health Minister Aaron Motsoaledi told Bhekisisa 's TV show, Health Beat, in July , that he "would strongly consider" a ministerial advisory committee (MAC), like the one we had during the COVID ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

In a major advancement for global HIV prevention, the World Health Organisation (WHO) has officially recommended injectable ...

Gilead wins US approval for Yeztugo HIV prevention shot, but its $28,000 price sparks access concerns despite near-perfect ...